Lorlatinib is a kinase inhibitor for oral administration used to treat cancer. A kinase inhibitor is an enzyme inhibitor that can block the action of protein kinases.
Lorlatinib is used to treat a certain type of non-small cell lung cancer that has spread to other parts of the body. It is used only if your cancer has a specific genetic marker (an abnormal "ALK" gene). Your doctor will test you for this gene.
Lorlatinib is given after other cancer treatments did not work or have stopped working.
Lorlatinib was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, some people responded to lorlatinib, but further studies are needed.
